Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis

المؤلفون المشاركون

Li, Zhanyi
Liu, Yu
Li, Xiangyong
Wu, Yuankai
Yang, Fangji
Mo, Qiwan
Chong, Yutian

المصدر

BioMed Research International

العدد

المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-11، 11ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2020-10-29

دولة النشر

مصر

عدد الصفحات

11

التخصصات الرئيسية

الطب البشري

الملخص EN

Primary biliary cholangitis (PBC) is a common condition that usually shows a progressive course towards cirrhosis without adequate treatment.

Growth differentiation factor 15 (GDF15) plays multiple roles in various pathological conditions.

The overall role of circulating GDF15 in cirrhotic PBC requires further investigation.

Twenty patients with cirrhotic PBC, 26 with non-cirrhotic PBC, and 10 healthy subjects were enrolled between 2014 and 2018, and the serum levels of GDF15 were measured via enzyme immunoassay.

The correlations between serum GDF15, weight, biochemical parameters, and the prognosis were analysed.

Serum levels of GDF15 were significantly higher in cirrhotic PBC patients than in non-cirrhotic PBC patients or healthy controls (p=0.009 and p<0.001, respectively).

The circulating GDF15 levels strongly correlated with weight changes (r=−0.541, p=0.0138), albumin (r=−0.775, p<0.0001), direct bilirubin (r=−0.786, p<0.0001), total bile acids (r=0.585, p=0.007), and C-reactive protein (r=0.718, p=0.0005).

Moreover, circulating GDF15 levels strongly correlated with the Mayo risk score (r=0.685, p=0.0009) and Model for End-stage Liver Disease score (r=0.687, p=0.0008).

Determined by the area under the receiver operating characteristic curves, the overall diagnostic accuracies of GDF15 were as follows: cirrhosis=0.725 (>3646.55 pg/mL, sensitivity: 70.0%, specificity: 69.2%), decompensated cirrhosis=0.956 (>4073.30 pg/mL, sensitivity: 84.62%, specificity: 100%), and cirrhotic biochemical non-responders = 0.835 (>3479.20 pg/mL, sensitivity: 71.43%, specificity: 92.31%).

GDF15 may be a useful and integrated biochemical marker to evaluate not only the disease severity and prognosis but also the nutrition and response to treatment of cirrhotic PBC patients, and its overall performance is satisfactory.

Therapy targeting GDF15 is likely to benefit cirrhotic PBC patients and is worth further research.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Li, Zhanyi& Liu, Yu& Li, Xiangyong& Wu, Yuankai& Yang, Fangji& Mo, Qiwan…[et al.]. 2020. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1134537

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Li, Zhanyi…[et al.]. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1134537

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Li, Zhanyi& Liu, Yu& Li, Xiangyong& Wu, Yuankai& Yang, Fangji& Mo, Qiwan…[et al.]. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1134537

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1134537